NAMS Menopause Certification Exam Study
Guide | 200 Comprehensive MCQs, Verified
Answers & Rationales (Latest Update)
Question 1
According to the STRAW+10 (Stages of Reproductive Aging Workshop) criteria, what is the
principal clinical marker determining the transition from early menopausal transition (Stage -
2) to late menopausal transition (Stage -1)?
A) An elevated serum FSH level > 25 IU/L measured on day 3 of the cycle.
,B) An interval of amenorrhea lasting 60 days or more.
C) A persistent change of 7 days or more in the length of consecutive menstrual cycles.
D) The development of moderate-to-severe vasomotor symptoms.
Verified Answer: B) An interval of amenorrhea lasting 60 days or more.
Explanation: The STRAW+10 criteria define Stage -2 (early transition) by a persistent
change of 7 days or more in consecutive cycle length. Stage -1 (late transition) is
characterized by the occurrence of amenorrhea lasting 60 days or longer, reflecting
increased frequency of anovulatory cycles. While FSH levels rise during this time, cycle
variability makes biochemical testing less definitive than clinical bleeding patterns.
Question 2
A 51-year-old woman presents with severe vasomotor symptoms. She has an intact uterus.
Which of the following FDA-approved tissue-selective estrogen complexes (TSEC)
combines a selective estrogen receptor modulator (SERM) with an estrogen to treat her
symptoms without requiring a progestogen?
A) Conjugated estrogens / bazedoxifene
B) Estradiol / norethindrone acetate
C) Ethinyl estradiol / norethindrone
D) Conjugated estrogens / medroxyprogesterone acetate
Verified Answer: A) Conjugated estrogens / bazedoxifene
Explanation: Conjugated estrogens combined with bazedoxifene (CE/BZA) is a tissue-
selective estrogen complex (TSEC). Bazedoxifene acts as an estrogen antagonist in the
endometrium, protecting it against estrogen-induced hyperplasia without the need for a
progestogen. This options is ideal for women with an intact uterus who experience
progestogen-related side effects.
Question 3
,Which non-hormonal medication is FDA-approved specifically for the treatment of
moderate-to-severe vasomotor symptoms associated with menopause by targeting the KNDy
(kisspeptin/neurokinin B/dynorphin) neurons in the hypothalamus?
A) Paroxetine mesylate
B) Gabapentin
C) Fezolinetant
D) Clonidine
Verified Answer: C) Fezolinetant
Explanation: Fezolinetant is a selective neurokinin 3 (NK3) receptor antagonist. It directly
targets the KNDy neurons in the thermoregulatory center of the hypothalamus to reduce
the frequency and severity of hot flashes. Paroxetine mesylate is also FDA-approved for
hot flashes but acts as an SSRI, not via the NK3 receptor pathway.
Question 4
A 47-year-old woman requests an evaluation for perimenopausal symptoms. Her laboratory
results show an elevated follicular phase serum follicle-stimulating hormone (FSH) level of
32 IU/L. What is the most appropriate clinical interpretation of this lab value?
A) The patient has officially reached menopause and can stop using contraception.
B) The patient is in the perimenopausal transition, but the value can fluctuate wildly, so it
cannot rule out future ovulation.
C) The patient has primary ovarian insufficiency (POI).
D) The patient requires immediate high-dose estrogen therapy to prevent osteoporosis.
Verified Answer: B) The patient is in the perimenopausal transition, but the value can
fluctuate wildly, so it cannot rule out future ovulation.
Explanation: During the perimenopausal transition, inhibin levels drop, causing FSH to
rise. However, hormonal fluctuations are erratic; a single elevated FSH level does not
mean ovulation will not occur in subsequent cycles. Contraception is still required until 12
consecutive months of amenorrhea have passed.
, Question 5
When evaluating a symptomatic 54-year-old postmenopausal woman for hormone therapy
(HT), which of the following clinical scenarios presents an absolute contraindication to
initiating systemic estrogen therapy?
A) Well-controlled primary hypertension
B) Controlled type 2 diabetes mellitus
C) History of unprovoked deep vein thrombosis (DVT) or pulmonary embolism
D) Surgical history of cholecystectomy
Verified Answer: C) History of unprovoked deep vein thrombosis (DVT) or pulmonary
embolism
Explanation: A history of active or past thromboembolic disease (DVT, PE, stroke, or
myocardial infarction) is an absolute contraindication to systemic estrogen therapy due to
the increased risk of thrombotic events. Managed hypertension, controlled diabetes, and a
prior cholecystectomy are not absolute contraindications.
Question 6
A 52-year-old postmenopausal woman with severe genitourinary syndrome of menopause
(GSM) reports painful intercourse (dyspareunia). She has tried over-the-counter vaginal
moisturizers without relief. She has no history of breast or endometrial cancer. What is the
recommended first-line prescription therapy?
A) High-dose oral conjugated estrogens
B) Low-dose local vaginal estrogen therapy (cream, insert, or ring)
C) Systemic transdermal estradiol patch
D) Oral medroxyprogesterone acetate
Verified Answer: B) Low-dose local vaginal estrogen therapy (cream, insert, or ring)
Explanation: For isolated genitourinary syndrome of menopause (GSM) symptoms that
fail to respond to over-the-counter lubricants or moisturizers, low-dose local vaginal
estrogen is the preferred first-line prescription treatment. Systemic absorption is minimal,
so a progestogen for endometrial protection is not required.
Guide | 200 Comprehensive MCQs, Verified
Answers & Rationales (Latest Update)
Question 1
According to the STRAW+10 (Stages of Reproductive Aging Workshop) criteria, what is the
principal clinical marker determining the transition from early menopausal transition (Stage -
2) to late menopausal transition (Stage -1)?
A) An elevated serum FSH level > 25 IU/L measured on day 3 of the cycle.
,B) An interval of amenorrhea lasting 60 days or more.
C) A persistent change of 7 days or more in the length of consecutive menstrual cycles.
D) The development of moderate-to-severe vasomotor symptoms.
Verified Answer: B) An interval of amenorrhea lasting 60 days or more.
Explanation: The STRAW+10 criteria define Stage -2 (early transition) by a persistent
change of 7 days or more in consecutive cycle length. Stage -1 (late transition) is
characterized by the occurrence of amenorrhea lasting 60 days or longer, reflecting
increased frequency of anovulatory cycles. While FSH levels rise during this time, cycle
variability makes biochemical testing less definitive than clinical bleeding patterns.
Question 2
A 51-year-old woman presents with severe vasomotor symptoms. She has an intact uterus.
Which of the following FDA-approved tissue-selective estrogen complexes (TSEC)
combines a selective estrogen receptor modulator (SERM) with an estrogen to treat her
symptoms without requiring a progestogen?
A) Conjugated estrogens / bazedoxifene
B) Estradiol / norethindrone acetate
C) Ethinyl estradiol / norethindrone
D) Conjugated estrogens / medroxyprogesterone acetate
Verified Answer: A) Conjugated estrogens / bazedoxifene
Explanation: Conjugated estrogens combined with bazedoxifene (CE/BZA) is a tissue-
selective estrogen complex (TSEC). Bazedoxifene acts as an estrogen antagonist in the
endometrium, protecting it against estrogen-induced hyperplasia without the need for a
progestogen. This options is ideal for women with an intact uterus who experience
progestogen-related side effects.
Question 3
,Which non-hormonal medication is FDA-approved specifically for the treatment of
moderate-to-severe vasomotor symptoms associated with menopause by targeting the KNDy
(kisspeptin/neurokinin B/dynorphin) neurons in the hypothalamus?
A) Paroxetine mesylate
B) Gabapentin
C) Fezolinetant
D) Clonidine
Verified Answer: C) Fezolinetant
Explanation: Fezolinetant is a selective neurokinin 3 (NK3) receptor antagonist. It directly
targets the KNDy neurons in the thermoregulatory center of the hypothalamus to reduce
the frequency and severity of hot flashes. Paroxetine mesylate is also FDA-approved for
hot flashes but acts as an SSRI, not via the NK3 receptor pathway.
Question 4
A 47-year-old woman requests an evaluation for perimenopausal symptoms. Her laboratory
results show an elevated follicular phase serum follicle-stimulating hormone (FSH) level of
32 IU/L. What is the most appropriate clinical interpretation of this lab value?
A) The patient has officially reached menopause and can stop using contraception.
B) The patient is in the perimenopausal transition, but the value can fluctuate wildly, so it
cannot rule out future ovulation.
C) The patient has primary ovarian insufficiency (POI).
D) The patient requires immediate high-dose estrogen therapy to prevent osteoporosis.
Verified Answer: B) The patient is in the perimenopausal transition, but the value can
fluctuate wildly, so it cannot rule out future ovulation.
Explanation: During the perimenopausal transition, inhibin levels drop, causing FSH to
rise. However, hormonal fluctuations are erratic; a single elevated FSH level does not
mean ovulation will not occur in subsequent cycles. Contraception is still required until 12
consecutive months of amenorrhea have passed.
, Question 5
When evaluating a symptomatic 54-year-old postmenopausal woman for hormone therapy
(HT), which of the following clinical scenarios presents an absolute contraindication to
initiating systemic estrogen therapy?
A) Well-controlled primary hypertension
B) Controlled type 2 diabetes mellitus
C) History of unprovoked deep vein thrombosis (DVT) or pulmonary embolism
D) Surgical history of cholecystectomy
Verified Answer: C) History of unprovoked deep vein thrombosis (DVT) or pulmonary
embolism
Explanation: A history of active or past thromboembolic disease (DVT, PE, stroke, or
myocardial infarction) is an absolute contraindication to systemic estrogen therapy due to
the increased risk of thrombotic events. Managed hypertension, controlled diabetes, and a
prior cholecystectomy are not absolute contraindications.
Question 6
A 52-year-old postmenopausal woman with severe genitourinary syndrome of menopause
(GSM) reports painful intercourse (dyspareunia). She has tried over-the-counter vaginal
moisturizers without relief. She has no history of breast or endometrial cancer. What is the
recommended first-line prescription therapy?
A) High-dose oral conjugated estrogens
B) Low-dose local vaginal estrogen therapy (cream, insert, or ring)
C) Systemic transdermal estradiol patch
D) Oral medroxyprogesterone acetate
Verified Answer: B) Low-dose local vaginal estrogen therapy (cream, insert, or ring)
Explanation: For isolated genitourinary syndrome of menopause (GSM) symptoms that
fail to respond to over-the-counter lubricants or moisturizers, low-dose local vaginal
estrogen is the preferred first-line prescription treatment. Systemic absorption is minimal,
so a progestogen for endometrial protection is not required.
